Could gene therapy cure HIV?

Sheykhhasan, Mohsen; Manoochehri, Hamed; Khoei, Saeideh Gholamzadeh; Poondla, Naresh; Saidijam, Massoud

doi:10.1016/j.lfs.2021.119451

Cited by 12 publications

(3 citation statements)

References 173 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S1 ). Although advanced medical methods could ensure the quality of life of infected people, such as antiretroviral therapy (ART) and gene therapy for human immunodeficiency virus (HIV) 1 , 2 , antiviral therapies for hepatitis B virus (HBV) 3 and hepatitis C virus (HCV) 4 , 5 , the high smoking rate among infected people often led to poor efficacy 6 – 8 . For instance, tobacco smoking cessations among HIV and HCV infected people could increase the treatment efficiency by 76% 6 .…”

Section: Introductionmentioning

confidence: 99%

Estimates of prevalence, time-trend, and association of smoking in adults living with HIV, HBV, and HCV (NHANES 1999–2018)

Yang

Lin

Liu

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Although the smoking rate of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infected people was much higher than that of the general population, smoking cessation interventions have long been ineffective. We aimed to examine the estimates of prevalence, time-trend, and association of smoking among people living with HIV, HBV, or HCV. This cohort was composed of 32,115 individuals from the NHANES database (1999–2018) and they were collected in the US. The time trend analysis of smoking and quitting rates was conducted using different years of survey follow-up and different infected groups. Multivariable logistic regression analysis was used to identify the risk factors related to smoking behavior of these infected people. Compared to non-infected smokers, infected smokers were more likely to be older (aged 30–39, OR = 9.92, CI 6.07–16.21; aged 40–49,OR = 3.51, CI 2.49–4.94), males (1.99, 1.54–2.55), lower education and economic level (1.78, 1.39–2.29; 2.05, 1.59–2.65), unemployed (1.63, 1.21–2.20), suffering depression (1.35, 1.05–1.72), and drug users (7.65, 5.04–11.59). Taken together, our study showed that these complex psychosocial characteristics and unhealthy behavioral factors might be major independent risk factors for increasing smoking rate and decreasing smoking cessation rate among these infected people.

show abstract

Section: Introductionmentioning

confidence: 99%

Estimates of prevalence, time-trend, and association of smoking in adults living with HIV, HBV, and HCV (NHANES 1999–2018)

Yang

Lin

Liu

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Furthermore, as T cells are key players in tackling viral infections, such as infections caused by the human immunodeficiency virus (HIV). This infection is also considered as a potential candidate for CAR T cell–based therapies 7 . Moreover, hepatitis B, hepatitis C, human cytomegalovirus, Epstein‐Barr virus, and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are recent examples of the diseases for which CAR T cell therapy has been proposed as a treatment.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer

Mohammadi

Akhoundi

Malih

et al. 2022

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapy has made improvements due to the advances in chimaeric antigen receptor (CAR) T cell development, offering a promising treatment option for patients who have failed to respond to traditional treatments. In light of the successful use of adoptive CAR T cell therapy for cancer, researchers have been inspired to develop CARs for the treatment of other diseases beyond cancers such as viral infectious diseases. Nonetheless, various obstacles limit the efficacy of CAR T cell therapies and prevent their widespread usage. Severe toxicities, poor in vivo persistence, antigen escape, and heterogeneity, as well as off-target effect, are key challenges that must all be addressed to broaden the application of CAR T cells to a wider spectrum of diseases. The key advances in CAR T cell treatment for cancer and viral infections are reviewed in this article. We will also discuss revolutionary CAR T cell products developed to improve and enhance the therapeutic advantages of these treatments.

show abstract

“…WHO’s 2019 report highlighted the grim situation of AIDS, which is a significant global public health issue; ~ 38 million people are living with AIDS. Furthermore, HIV/AIDS has claimed almost 33 million lives so far [ 1 , 2 ]. Mechanically, AIDS is initiated by HIV infection, which specifically targets the human immune system (especially CD4 + T cells), initiating the infectious cycle [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial

et al. 2021

View full text Add to dashboard Cite

Introduction HS-10234, a novel prodrug of tenofovir (TFV), functions by inhibiting nucleotide reverse transcriptase against retroviral infections including hepatitis B virus and human immunodeficiency virus (HIV). As it is a possible substitute for TFV co-administration with emtricitabine, determining the drug-drug interactions (DDI) between HS-10234 and emtricitabine therapy will be helpful for researchers to design and conduct future phase II/III studies and merits careful examination in the era of evolving new combination antiretroviral therapy regimens. Methods We conducted an open-label, two-sequence, two-period, self-controlled phase I trial that enrolled 36 healthy volunteers randomized into two groups (group 1 and group 2). Eighteen subjects in group 1 were orally administered HS-10234 at a 25-mg daily dose for 7 days during period 1 (D1–D7) followed by co-administration of emtricitabine at a 200-mg dose once daily (QD) for 7 additional days during period 2 (D8–D14). Participants in group 2 were orally administered emtricitabine 200 mg QD for 7 days during period 1 (D1–D7) and then co-administered HS-10234 25 mg QD for 7 additional days during period 2 (D8–D14). Pharmacokinetics (PK) of HS-10234 and emtricitabine were characterized when administered alone and in combination. The concentrations of HS-10234 and its metabolites TFV and emtricitabine were determined using high performance liquid chromatography-mass spectrometry (HPLC-MS)/MS. Peripheral blood monocyte cells (PBMCs) were isolated for detection of intracellular concentrations of HS-10234’s active metabolite, intracellular tenofovir diphosphate (TFV-DP) pre-dose and 2, 4, 8, 12 and 24 h post-dose on D7 and D14 in group 1. WinNonlin software was used to calculate PK parameters. Results After multiple-dose administration of HS-10234 with emtricitabine, the AUC 0–tau of HS-10234 and TFV-DP was 1.327- and 1.403-fold higher than that with HS-10234 administration alone. The C max and AUC 0–tau were increased 1.120- and 1.077-fold compared to emtricitabine administration alone. Co-administration of HS-10234 with oral emtricitabine was well tolerated. No serious adverse events were observed. Conclusions Although a slightly increased steady-state PK exposure of HS-10234 and TFV-DP was observed with co-administration of oral HS-10234 with emtricitabine, these changes were not considered clinically relevant. Thus, dose adjustments are not recommended for HS-10234 combination with emtricitabine. Trial Registration NCT04477096, July 20, 2020.

show abstract

Could gene therapy cure HIV?

Cited by 12 publications

References 173 publications

Estimates of prevalence, time-trend, and association of smoking in adults living with HIV, HBV, and HCV (NHANES 1999–2018)

Estimates of prevalence, time-trend, and association of smoking in adults living with HIV, HBV, and HCV (NHANES 1999–2018)

Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer

Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial

Contact Info

Product

Resources

About